Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Jun 16;(6):CD007402. doi: 10.1002/14651858.CD007402.pub2

Table 1. Summary of outcomes: successful treatment.

Study ID Treatment Clinical response Other response
Airaksinen 1993
  • (1)

    Ketoprofengel, 2 × 5 g (125 mg) daily, n = 29

  • (2)

    Placebo gel, n = 27

PGE “improved” at 7 days
  • (1)

    24/29

  • (2)

    14/27

No additional data
Akermark 1990
  • (1)

    Indomethacin spray 1% (Elmetacin), 3-5 × 0.5-1.5 ml daily, n = 23

  • (2)

    Indomethacin capsules, 3 × 25 mg daily, n = 23

  • (3)

    Placebo spray and capsules, n = 24

No pain on palpation at 7 days
  • (1)

    12/22

  • (2)

    5/22

  • (3)

    6/24

Patient assessment of improvement at 7 days (Scale 0-100)
  • (1)

    57

  • (2)

    49

  • (3)

    30

Aoki 1984
  • (1)

    Piroxicamgel 5%, 3-4 × 1 g daily, n = 84

  • (2)

    Indomethacin gel 1 %, 3-4 × 1 g daily, n = 84

  • (3)

    Placebo gel, n = 84

PGE (5 point) “better or much better” at 7 days
  • (1)

    56/72

  • (2)

    41/64

  • (3)

    33/67

Pain on movement “reduced” or “disappeared” at 7 days:
  • (1)

    48/61

  • (2)

    38/60

  • (3)

    35/63

Auclair 1989
  • (1)

    Niflumic acid gel 2.5%, 3× 5 g daily, n = 117

  • (2)

    Placebo gel, n = 110

PGE (5 point) “good or very good” at 7 days
  • (1)

    69/117

  • (2)

    54/110

Pain on palpation “improved” at 7 days
  • (1)

    69/117

  • (2)

    53/110

Billigmann 1996
  • (1)

    Ibuprofen microgel 5%, 3× 200 mg daily, n = 80

  • (2)

    Placebo gel , n = 80

Complete remission
  • (1)

    25/80

  • (2)

    10/80

Improvement in pain with movement of 20% at 7 days
  • (1)

    65/80

  • (2

    55/80

Campbell 1994
  • (1)

    Ibuprofen cream 5% (Proflex), 4 × 4“ daily, n = 26

  • (2)

    Placebo cream, n = 25

Improvement in walking ability (4 point) at 7 days
  • (1)

    21/26

  • (2)

    19/25

No additional data
Chatterjee 1977
  • (1)

    Benzydamine HCl cream 3%, 3 × daily, n = 25

  • (2)

    Placebo cream, n = 25

Pain on movement “absent/slight” at 6 days
  • (1)

    21/25

  • (2)

    12/25

Tenderness with pressure “absent/slight” at 6 days
  • (1)

    21/25

  • (2)

    12/25

Curioni 1985
  • (1)

    Ibuproxam, n = 20

  • (2)

    Ketoprofen, n = 20

  • (3)

    Etofenamate, n = 20

Resolution of symptoms by 7 days
  • (1)

    15/20

  • (2)

    13/20

  • (3)

    13/20

PGE “good” or “excellent” at 10 days
  • (1)

    19/20

  • (2)

    not reported

  • (3)

    16/20

Diebshlag 1990
  • (1)

    Ketorolac gel 2%, 3 × 3 g daily, n= 13

  • (2)

    Etofenamate gel 5%, 3 × 3 g daily, n = 12

  • (3)

    Placebo gel, n = 12

Improvement in pain at 7 days
  • (1)

    12/13

  • (2)

    10/12

  • (3)

    9/12

No additional data
Dreiser 1988
  • (1)

    Ibuprofen cream 5%, 3 × 4cm daily, n = 32 (3 × 10 cm for large joints)

  • (2)

    Placebo cream, n = 32

PGE “improvement” or “complete relief” at 7 days
  • (1)

    26/32

  • (2)

    12/32

(1) significantly better than (2) for mean improvement in spontaneous pain, movement pain, rest pain, tenderness to pressure (VAS)
Dreiser 1989
  • (1)

    Ketoprofen gel 2.5%, 2 × 5cm daily, n = 30

  • (2)

    Placebo gel, n = 30

PGE (3 point) “better” at 7 days
  • (1)

    18/30

  • (2)

    5/30

(1) significantly better than (2) for mean improvement in pain (rest and movement) (VAS)
Dreiser 1990
  • (1)

    Niflumic acid gel 2.5%, 3 × 5 g daily, n = 30

  • (2)

    Placebo gel, n = 30

PGE (4 point) “cured” or “improved” at 7 days
  • (1)

    23/30

  • (2)

    10/30

(1) significantly better than (2) for mean improvement in pain (VAS)
Dreiser 1994
  • (1)

    Flurbiprofen patch, 2 × 40 mg daily, n = 65

  • (2)

    Placebo patch, n = 66

PGE (4 point) “good” or “very good” at 7 days
  • (1)

    48/65

  • (2)

    41/66

(1) significantly better than (2) for mean improvement in spontaneous pain, but not pain on movement or palpation (VAS)
Fioravanti 1999
  • (1)

    DHEP lecithin gel, 3 × 5 g (=65 mg) daily, n = 50

  • (2)

    DHEP gel, 3 × 5 g (=65 mg) daily, n = 50

PGE (4 point) “good” or “excellent” at 10 days
  • (1)

    35/50

  • (2)

    35/50

(1) significantly better than (2) for mean improvement in spontaneous pain at 7 days, but not for pain on movement at 10 days (VAS)
Fujimaki 1985
  • (1)

    Piroxicam gel 0.5%, 3-4 × 1 g daily, n = 92

  • (2)

    Indomethacin gel 1 %, 3-4 × 1 g daily, n = 90

  • (3)

    Placebo gel, n = 89

PGE (5 point) “better” or “much better” at end of treatment at 14 days
  • (1)

    44/83

  • (2)

    44/82

  • (3)

    40/82

No additional data
Gallacchi 1990
  • (1)

    Diclofenac hydroxyethylpyrroli-dine gel 1%, 4 × 2 g daily, n = 25 (Flector gel)

  • (2)

    Diclofenac sodium 1%, 4 × 2 g daily, n = 25 (Voltaren Emugel)

PGE (5 point) “good” or “excellent” at 14 days
  • (1)

    19/25

  • (2)

    19/25

No significant difference between groups for pain on applied pressure at 7 and 14 days
Governali 1995
  • (1)

    Ketoprofen gel 5%, 3 × 2-3 g daily, n = 15

  • (2)

    Ketoprofen cream 1%, 3 × 2-3 g daily, n = 15

PGE (5 point) “good” or “excellent” at 7 days
  • (1)

    14/15

  • (2)

    4/15

No additional data
Gualdi 1987
  • (1)

    Flunaxaprofen gel, 2 × 3-5 cm daily, n = 30

  • (2)

    Ketoprofen gel, 2 × 3-5 cm daily, n = 30

No dichotomous data No significant difference between groups for pain on movement at 7 days
Haig 1986
  • (1)

    Benzydamine cream 3%, 6 × daily, n = 21

  • (2)

    Placebo cream, n = 22

Pain on movement “improved” by 6 days
  • (1)

    18/21

  • (2)

    13/22

No additional data
Hofman 2000
  • (1)

    Diclofenac sodium gel 1%, 4 × 2 cm daily, n = 69

  • (2)

    Lysine clonixinate gel 5%, 4 × 2 cm (22.5 mg) daily, n = 73

PGE (3 point) at 8 days: “good”
  • (1)

    38/69

  • (2)

    36/73

No significant difference between treatments for any pain outcomes
Hosie 1993
  • (1)

    Felbinac foam 3%, 3 × 2g daily + placebo tabs, 3x1 daily, n = 140 (127 analysed for efficacy)

  • (2)

    Ibuprofen tablets, 3 × 400 mg daily + placebo foam, 3 × 2g daily, n = 147 (134 analysed for efficacy)

Pain on movement “none” or “mild” at 7 days
  • (1)

    81/127

  • (2)

    96/133

Spontaneous pain “none” or “mild” at 7 days
  • (1)

    99/127

  • (2)

    108/134

Jenoure 1997
  • (1)

    DHEP plaster (Tissugel), 2 × daily, n = 44

  • (2)

    Placebo plaster 2 × daily, n = 41

Baseline pain in two groups not balanced, and data in table and figure do not agree, so efficacy outcomes not used No additional data
Joussellin 2003
  • (1)

    DHEP plaster (Flector Tissugel 1%), 1 × daily, n = 68

  • (2)

    Placebo plaster 1 × daily, n = 66

PGE (4 point) “excellent” at 7 days
  • (1)

    36/68

  • (2)

    24/66

(1) significantly better than (2) for mean pain on movement at 6 days
Julien 1989
  • (1)

    Ketoprofen gel 2.5%, 2 × 5cm (= 50 mg) daily, n = 30

  • (2)

    Placebo gel, n = 30

PGE (4 point) “recovered” at 7 days
  • (1)

    18/30

  • (2)

    6/30

PGE (4 point) “recovered” or “improved” at 7 days
  • (1)

    25/30

  • (2)

    13/30

Kockelbergh 1985
  • (1)

    Ketoprofen gel 2.5%, 2 × 5cm (= 15 mg) daily, n = 38

  • (2)

    Placebo gel, n = 36

PGE (3 point) “good” at 7 days
  • (1)

    30/38

  • (2)

    22/36

(1) and (2) slightly better than (3) for mean spontaneous pain at 7 days
Linde 1985
  • (1)

    Benzydamine 3% cream, 3 × daily, n = 50

  • (2)

    Placebo gel, n = 50

No pain on movement (walking) at 8 days
  • (1)

    35/50

  • (2)

    40/50

No additional data
Machen 2002
  • (1)

    Ibuprofen gel 5%, 3 × daily, n = 40

  • (2)

    Placebo gel, n = 41

PGE: (5 point) “marked improvement” or “complete clearance” at 7 days
  • (1)

    25/40

  • (2)

    9/41

Clinically meaningful (≥30 mm) pain relief at day 7
  • (1)

    30/40

  • (2)

    16/41

Mahler 2003
  • (1)

    DHEP + lethicin gel, 3 × 5 g daily, n = 52

  • (2)

    DHEP gel, 3 × 5 g daily, n = 48

PGE (4 point) “good” or “excellent” at 10 days
  • (1)

    49/52

  • (2)

    39/48

Mean reduction in pain on movement at 3 and 10 days significantly greater with (1)than (2)
Mazieres 2005a
  • (1)

    Ketoprofen patch 100 mg, once daily, n=81

  • (2)

    Placebo patch, n=82

PGE (4 point) “good” or “excellent” at 14 days
  • (1)

    50/87

  • (2)

    41/85

All mean efficacy measures improved more for (1) than (2), most were statistically significant
Mazieres 2005b
  • (1)

    Ketoprofen patch 100 mg, once daily, n=87

  • (2)

    Placebo patch, n=85

PGE (4 point) “good” or “excellent” at 14 days
  • (1)

    72/81

  • (2)

    60/82

All mean efficacy measures improved more for (1) than (2), most were statistically significant
McLatchie 1989
  • (1)

    Felbinac gel 3%, 3 × 3 cm daily, n = 118

  • (2)

    Placebo gel, n = 113

No dichotomous data Patient daily self-assessment for mean pain on rest, movement, at night, interference with normal and leisure activities show better efficacy for (1) than (2) from day 2 (VAS)
Morris 1991
  • (1)

    Felbinac gel 3%, 3×1 cm daily, n = 41

  • (2)

    Placebo gel, n = 43

PGE (5 point) “good” or “very good” at 7 days
  • (1)

    23/41

  • (2)

    27/43

(1) better than (2) for mean improvement in symptoms and sporting function at 7 days
Noret 1987
  • (1)

    Ketoprofen gel 2.5%, 2 × 5cm (7.5 mg) daily, n = 48

  • (2)

    Placebo gel, n = 45

PGE (4 point) “good” or “excellent” at 8 days
  • (1)

    39/51

  • (2)

    9/47

Decrease in mean spontaneous pain significantly greater in (1) than (2) by 3 days
Parrini 1992
  • (1)

    Ketoprofen foam 15%, 3 × 2 g (200 mg) daily, n = 83

  • (2)

    Placebo foam, n = 86

No dichotomous data Mean pain on movement and pressure significantly decreased by 7 days in (1) compared with (2)
Picchio 1981
  • (1)

    Ibuprofen gel 10%, 3 × daily , n = 20

  • (2)

    Ketoprofen gel 1%, 3 × daily, n = 20

No pain on movement at 8 days
  • (1)

    3/20

  • (2)

    0/20

Spontaneous pain “none” at 8 days
  • (1)

    6/20

  • (2)

    0/20

Predel 2004
  • (1)

    Diclofenac sodium patch, 2 × daily (140 mg/patch), n = 60

  • (2)

    Placebo patch, n = 60

PGE (4 point) “good” “excellent” at 7 days
  • (1)

    55/60

  • (2)

    5/60

(1) better than (2) for reduction in tenderness, pain, and speed of pain reduction
Ramesh 1983
  • (1)

    Ibuprofen cream 5%, 3-4 × 510 cm daily, n = 40

  • (2)

    Placebo cream, n = 40

Pain on movement (4 point) “none” or “slight” at 7 days
  • (1)

    23/40

  • (2)

    23/40

Physician global assessment at 10 days: “good”
  • (1)

    29/40

  • (2)

    16/40

Rowbotham 2003
  • (1)

    Diclofenac epolamine patch (Flector Tissuegel) 2 × daily (equivalent to 140 mg diclofenac sodium/patch), n = 191

  • (2)

    Placebo patch, n = 181

Pain intensity ≤2/10 for 2 days or 4 consecutive evaluations, by 7 days
  • (1)

    75/191

  • (2)

    48/181

Mean pain on rest significantly better with (1) than (2) after 7 days
Russell 1991
  • (1)

    Piroxicam gel 0.5%, 4x5 mg daily, n = 100

  • (2)

    Placebo gel, n = 100

PGE (4 point) “good” or “excellent” at 8 days
  • (1)

    79/100

  • (2)

    45/100

Statistically greater red in mean pain on movement at 8 days with (1) than (2)
Sanguinetti 1989
  • (1)

    Felbinac gel 3%, 3 × daily, n = 42

  • (2)

    Placebo gel, n = 40

PGE “good” or “very good” at 7 days
  • (1)

    34/42

  • (2)

    11/40

(1) better than (2) by 2 days
Sinneger 1981
  • (1)

    Fentiazac cream 5%, 2-3 × daily, n= 10

  • (2)

    Placebo cream, n = 10

Complete pain reliefwithin 10 days
  • (1)

    7/10

  • (2)

    1/10

Improvement in active pain on movement at 5 days
  • (1)

    67%

  • (2)

    32%

Spacca 2005
  • (1)

    DHEP lecithin gel (Effigel), 3 × 5 g, daily, n = 79

  • (2)

    Placebo gel, n = 76

No dichotomous data Mean pain scores improved more rapidly in (1) than (2) - statistically significant at 3 and 6 days
Sugioka 1984
  • (1)

    Piroxicam gel 0.5%, 3-4 × 1 g daily, n = 183

  • (2)

    Indomethacin gel 1 %, 3-4 × 1 g daily, n = 183

PGE (5 point) “better” or “much better” at 14 days
  • (1)

    85/175

  • (2)

    55/165

Pain on movement “reduced” or “disappeared” at 7 days
  • (1)

    77/175

  • (2)

    63/165

Thorling 1990
  • (1)

    Naproxen gel 10%, 2-6 × daily, n = 60

  • (2)

    Placebo gel, n = 60

PGE (5 point) “good” or “very good” at 7 days
  • (1)

    38/60

  • (2)

    27/60

Participants using naproxen improved more rapidly and had significantly lower severity scores by day 3
Tonutti 1994
  • (1)

    Ketoprofen gel 5%, 3 × 2-3 g daily, n = 15

  • (2)

    Etofenamate gel 5%, 3 × 2-3 g, n= 15

PGE (4 point) “good” or “excellent” at 7 days
  • (1)

    10/15

  • (2)

    11/15

Significant reductions in pain on movement by 7 days in both groups
Vecchiet 1989
  • (1)

    Meclofenamic acid gel 5%, 2 × 10 cm daily (2g), n = 30

  • (2)

    Placebo, n = 30

PGE (4 point) “good” or “excellent” at 10 days
  • (1)

    30/30

  • (2)

    19/30

(1) significantly better than (2) for mean improvement in spontaneous pain, movement pain, functional restriction
Whitefield 2002
  • (1)

    Ibuprofen gel 5% + placebo tablet, × 3 daily, n = 50

  • (2)

    Ibuprofen 400 mg tablet + placebo gel, × 3 daily, n = 50

Patient satisfied at 7 days
  • (1)

    30/50

  • (2)

    36/50

“Completely better” at 14 days
  • (1)

    24/50

  • (2)

    30/50

PGE - patient global evaluation; VAS - visual analogue scale